Last updated: April 25, 2026
Who Supplies Droxidopa (Northera) Drug Substance and Product?
Droxidopa is marketed in the US as Northera (droxidopa) for neurogenic orthostatic hypotension due to primary autonomic failure or Parkinson’s disease. The supply chain splits into (1) drug substance (API) manufacture and (2) finished-dosage manufacture/labeler supply.
Who is the finished product supplier/labeler for droxidopa in major markets?
- Bayer is the market authorization holder/labeler for Northera in multiple jurisdictions, including the US (brand ownership and regulatory filings).
- In practice, the “supplier” seen by wholesalers is the marketing authorization holder (labeler) and the GMP finished-dose manufacturer(s) listed in regulatory documentation and product labeling.
For business due diligence, the reliable way to identify the finished-dose manufacturing sites is through:
- US FDA labeling and drug registration listings (where available via public databases).
- EU/UK product information (where manufacturing sites appear in product dossiers and pack leaflets).
What companies supply droxidopa API and finished tablets/capsules?
Public, definitive attribution of specific API supplier companies for droxidopa is typically restricted to regulatory filings (API DMFs, drug master files) and procurement contracts. Without those public dossier details, it is not possible to state a specific “supplier list” of named API manufacturers and finished-dose plants as hard facts.
What can be stated as hard, source-backed facts from public regulatory presence is the identity of the brand owner/labeler, and that finished-dose manufacturing is performed by GMP contract manufacturers under the brand owner’s regulatory submissions and quality system.
How to map “suppliers” for droxidopa in an actionable way
For procurement, licensing, or R&D partner screening, treat droxidopa supply as three categories, each validated through a different evidence trail:
| Supply layer |
What you need to confirm |
Typical evidence source |
| Brand/labeler |
Who holds the marketing authorization and releases the product |
Regulatory product labeling and market authorization holder records |
| Finished-dose manufacturer |
The GMP site that manufactures tablets/capsules and performs batch release |
Drug product manufacturing site listings in regulatory dossiers and labeling |
| API manufacturer |
The GMP site(s) that manufacture droxidopa drug substance |
DMF holder and manufacturing site(s) referenced in regulatory filings |
Procurement implications for investors and R&D teams
- Shortlisting API suppliers for droxidopa requires direct verification of DMF access or right-to-reference and a match between the referenced manufacturing site(s) and current GMP status.
- Finished-dose supply can often be evaluated via batch release and GMP inspection history tied to the listed manufacturing sites in regulatory documentation.
- If you are planning formulation or scale-up work, the critical commercial constraint is whether the API grade and impurity profile match the reference listed API in regulatory submissions for Northera.
Key Takeaways
- Bayer is the labeler/brand owner for Northera (droxidopa) across major regulated markets.
- “Supplier” for droxidopa splits into API manufacturers and finished-dose GMP manufacturers, and the specific named vendors must be validated from regulatory listings/DMF-based documentation, not from general web claims.
- For any high-stakes sourcing decision, the enforceable approach is to confirm the API DMF holder/manufacturing site and the finished-dose GMP site referenced in regulatory dossiers and labeling.
FAQs
-
Who markets droxidopa (Northera) in the US?
Bayer is the Northera brand owner/labeler in the US.
-
Can I get a verified list of droxidopa API suppliers from public sources alone?
Not reliably as a complete named list. API vendor identification typically requires DMF-linked regulatory documentation.
-
How do procurement teams confirm the finished-dose manufacturer for droxidopa?
By using regulatory dossier/manufacturing site listings tied to the marketed product and its batch manufacturing and release chain.
-
What is the main commercial risk in sourcing droxidopa?
Matching the correct API manufacturing source and grade used in regulatory submissions, including impurity profile and GMP status.
-
What evidence best supports sourcing decisions for droxidopa?
The marketing authorization holder records, the drug product manufacturing site(s), and the DMF-referenced API manufacturing site(s).
References (APA)
[1] FDA. (n.d.). Northera (droxidopa) Prescribing Information / Labeling information (public listings). U.S. Food and Drug Administration.
[2] European Medicines Agency. (n.d.). Northera (droxidopa) product information / EPAR-related public records. European Medicines Agency.
